Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study
DOI:
https://doi.org/10.2340/actadv.v102.2412Keywords:
psoriasis, elderly, geriatric psoriasis, older adults, systemic treatment, treatment safetyAbstract
Optimal selection of systemic therapy in older adults with psoriasis can be challenging, due to sparse evidence-based guidance. This multicentre retrospective study investigated the safety of systemic therapy with causality assessment in a real-world cohort of older adults (≥ 65 years) with psoriasis. Data from 6 hospitals on (serious) adverse events were collected, causality assessment performed and incidence rate ratios calculated. Potential predictors for adverse events-occurrence were studied using multivariable logistic regression analysis. In total, 117 patients with 176 treatment episodes and 390 patient-years were included, comprising 115 (65.3%) and 61 (34.7%) treatment episodes with conventional systemic therapy and biologics/apremilast, respectively. After causality assessment, 232 of 319 (72.7%) adverse events remained and were analysed further, including 12 serious adverse events. No significant differences in incidence rate ratios were found between the systemic treatment types. In regression analysis, increasing age was associated with causality assessed adverse events-occurrence (odds ratio 1.195; p=0.022). Comorbidity, polypharmacy, and treatment type were not associated with causality assessed adverse events-occurrence. In conclusion, increasing age was associated with a higher causality assessed adverse events-occurrence. Causality assessed serious adverse events were rare, reversible and/or manageable in clinical practice. In conclusion, the safety profile of systemic antipsoriatic therapy within this population is reassuring.
Downloads
References
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identificantion and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
https://doi.org/10.1038/jid.2012.339 DOI: https://doi.org/10.1038/jid.2012.339
Hahnel E, Lichterfeld A, Blume-Peytavi U, Kottner J. The epidemiology of skin conditions in the aged: a systematic review. J Tissue Viability 2017; 26: 20-28.
https://doi.org/10.1016/j.jtv.2016.04.001 DOI: https://doi.org/10.1016/j.jtv.2016.04.001
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212.
https://doi.org/10.1111/jdv.13854 DOI: https://doi.org/10.1111/jdv.13854
Balato N, Patruno C, Napolitano M, Patrì A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging 2014; 31: 233-238.
https://doi.org/10.1007/s40266-014-0156-6 DOI: https://doi.org/10.1007/s40266-014-0156-6
Endo JO, Wong JW, Norman RA, Chang AL. Geriatric dermatology: Part I. Geriatric pharmacology for the dermatologist. J Am Acad Dermatol 2013; 68: 521.e1-521.e10.
https://doi.org/10.1016/j.jaad.2012.10.063 DOI: https://doi.org/10.1016/j.jaad.2012.10.063
van Winden MEC, Ter Haar ELM, Groenewoud JMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. Br J Dermatol 2021; 184: 759-762.
https://doi.org/10.1111/bjd.19665 DOI: https://doi.org/10.1111/bjd.19665
Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol 2020; 83: 412-424.
https://doi.org/10.1016/j.jaad.2019.07.079 DOI: https://doi.org/10.1016/j.jaad.2019.07.079
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
https://doi.org/10.1001/archdermatol.2011.2768 DOI: https://doi.org/10.1001/archdermatol.2011.2768
van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek J, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol 2020; 156: 1229-1239.
https://doi.org/10.1001/jamadermatol.2020.2311 DOI: https://doi.org/10.1001/jamadermatol.2020.2311
Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 2014; 94: 293-297.
https://doi.org/10.2340/00015555-1719 DOI: https://doi.org/10.2340/00015555-1719
Dickel H, Bruckner T, Höxtermann S, Dickel B, Trinder E, Altmeyer P. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 893-905.
https://doi.org/10.1111/jdv.15448 DOI: https://doi.org/10.1111/jdv.15448
Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open 2019; 9: e024537.
https://doi.org/10.1136/bmjopen-2018-024537 DOI: https://doi.org/10.1136/bmjopen-2018-024537
Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol 2015; 29: 858-864.
https://doi.org/10.1111/jdv.12688 DOI: https://doi.org/10.1111/jdv.12688
Naidu RP. Causality assessment: a brief insight into practices in pharmaceutical industry. Perspect Clin Res 2013; 4: 233-236.
https://doi.org/10.4103/2229-3485.120173 DOI: https://doi.org/10.4103/2229-3485.120173
van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol 2020; 100: adv00215.
https://doi.org/10.2340/00015555-3569 DOI: https://doi.org/10.2340/00015555-3569
Trettel A, Spehr C, Korber A, Augustin M. The impact of age on psoriasis health care in Germany. J Eur Acad Dermatol Venereol 2017; 31: 870-875.
https://doi.org/10.1111/jdv.14115 DOI: https://doi.org/10.1111/jdv.14115
Phan C, Sigal ML, Esteve E, Reguiai Z, Barthelemy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 78-82.
https://doi.org/10.1111/jdv.12850 DOI: https://doi.org/10.1111/jdv.12850
Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. Br J Dermatol 2016; 174: 579-587.
https://doi.org/10.1111/bjd.14331 DOI: https://doi.org/10.1111/bjd.14331
Napolitano M, Balato N, Ayala F, Patruno C, Patri A, Megna M, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol 2016; 151: 587-595.
Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 1288-1294.
https://doi.org/10.1016/j.jclinepi.2004.03.012 DOI: https://doi.org/10.1016/j.jclinepi.2004.03.012
Dutch College of General Practitioners, Huisartsen Genootschap, Nederlandse Vereniging voor Klinische Geriatrie, Orde van Medisch Specialisten. [Multidisciplinary guideline polypharmacy in elderly], Utrecht: Dutch College of General Practitioners, 2012. [accessed 2020 March 2] Available from: https://www.nhg.org/sites/default/files/content/nhg_org/ uploads/polyfarmacie_bij_ouderen.pdf (in Dutch).
Dutch Central Committee on Research Involving Human Subjects, Centrale Commissie Mensgebonden Onderzoek. CCMO. SAEs, SUSAR's en SADE's. [accessed 2020 Dec]. Available from https://www.ccmo.nl/onderzoekers/tijdens-en-na-het-onderzoek/saes-susars-en-sades (in Dutch).
World Health Organization (WHO) UMC, Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. 2018-04-06. [accessed 2021 May]. Available from http://www.who-umc.org/graphics/4409.pdf.
Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Real-world effectiveness and safety of apremilast in older patients with psoriasis. Drugs Aging 2020; 37: 657-663.
https://doi.org/10.1007/s40266-020-00781-y DOI: https://doi.org/10.1007/s40266-020-00781-y
R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing V, Austria. [accessed 2021 June]. Available from: https://www.R-project.org/.
Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol 2019; 33: 143-146.
https://doi.org/10.1111/jdv.15139 DOI: https://doi.org/10.1111/jdv.15139
Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 64-72.
https://doi.org/10.1016/j.jaad.2012.06.035 DOI: https://doi.org/10.1016/j.jaad.2012.06.035
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
https://doi.org/10.1016/0021-9681(87)90171-8 DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Additional Files
Published
How to Cite
License
Copyright (c) 2022 Elke L.M. ter Haar, Eline E. ten Bruin, Ewald E. Bronkhorst, Rinke J. Borgonjen, Marloes M. Kleinpenning, Else N. Kop, M. Birgitte Visch, Peter C.M. van de Kerkhof , Elke M.G.J. de Jong , Satish F.K. Lubeek
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
